How to access the content in Diálogo Roche?
To view the materials you must be registered in Diálogo Roche.
If you are not yet registered, you can do it here.
Add a shortcut to Diálogo Roche
Add a shortcut to Diálogo Roche: press and then add it to your home screen.
September 15
September 15
Non-Hodgkin's Lymphoma (NHL) represents 80-90% of cases, which have been increasing in recent years.
On the other hand, diffuse large B cell lymphoma (DLBCL) is the most common subtype of NHL, representing about 40% of patients. In the last two decades, improved knowledge of large B-cell lymphomas, in terms of epidemiology, prognostic factors, and biologic heterogeneity, has led to a refinement of disease classification and the development of new therapeutic approaches.
Dr. Christopher Flowers - MD Anderson Cancer Center
This material may contain information regarding drugs under investigation or indications not yet approved (off-label), with the sole purpose of medical and/or scientific education to Healthcare Professionals.
Roche does not recommend the use of any product in any indication, dosage or route of administration that is not clearly mentioned in the prescribing information for the product approved by the local regulatory authority. Roche does not request the prescription of the products in off-label indications, nor does it intend to promote it.
The views and opinions expressed in this material are the sole responsibility of the authors and do not necessarily represent the views of Roche.
How to access the content in Diálogo Roche?
To view the materials you must be registered in Diálogo Roche.
If you are not yet registered, you can do it here.
Registration is one-time only and will allow you access to all the events and educational contents of the portal.
If you are already registered, just click on the material you want to access
and log in with your credentials.